Preparation of the albumin nanoparticle system loaded with both paclitaxel and sorafenib and its evaluation in vitro and in vivo

References

• Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111: 1287–95
   PubMed Web of Science ®Google Scholar
• Carter CA, Chen C, Brink C, Vincent P, Maxuitenko YY, Gilbert KS, Waud WR, Zhang X. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Canc Chemother Pharmacol 2007; 59: 183–95
   PubMed Web of Science ®Google Scholar
• Chi LM, Wu WG. Mechanism of hemolysis of red blood cell mediated by ethanol. Biochim Biophys Acta (BBA) – Biomembranes 1991; 1062: 46–50
   PubMedGoogle Scholar
• Cristina RA. Pharmacogenomics of paclitaxel. Pharmacogenomics 2010; 11: 621–3
   PubMedGoogle Scholar
• Davidson NG. Single-agent paclitaxel as first-line treatment of metastatic breast cancer: The British experience. Semin Oncol 1996; 23: 6–10
   PubMedGoogle Scholar
• Desai NP, Tao C, Yang A, Louie L, Zheng TL, Yao ZW, Soon-Shiong P, Magdassi S, 1998. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof. WO98/14174
   Google Scholar
• Emmenegger U, Kerbel RS. Cancer: Chemotherapy counteracted. Nature 2010; 468: 637–8
   PubMed Web of Science ®Google Scholar
• Ferrara N. VEGF and the quest for tumor angiogenesis factors. Nat Rev Cancer 2002; 2: 795–803
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182–6
   PubMed Web of Science ®Google Scholar
• Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757–63
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol 2003; 13: 159–67
   PubMed Web of Science ®Google Scholar
• Guo XD, Tan JP, Kim SH, Zhang LJ, Zhang Y, Hedrick JL, Yang YY, Qian Y. Computational studies on self-assembled paclitaxel structures: Templates for hierarchical block copolymer assemblies and sustained drug release. Biomaterials 2009; 30: 6556–63
   PubMed Web of Science ®Google Scholar
• Haglund C, Aleskog A, Hakansson LD, Höglund M, Jacobsson S, Larsson R, Lindhagen E. The FMCA-GM assays, high throughput non-clonogenic alternatives to CFU-GM in preclinical hematotoxicity testing. Toxicol Lett 2010; 194: 102–7
   PubMed Web of Science ®Google Scholar
• Kolch W. Meaningful relationships: The regulation of the Ras/Raf /MEK/ERK pathway by protein interactions. Biochem J 2000; 351(Pt 2): 289–305
   PubMedGoogle Scholar
• Kratz F. Albumin as a drug carrier design of prodrugs, drug conjugates and nanoparticles. Journal of Control Release 2008; 132: 171–83
   PubMed Web of Science ®Google Scholar
• Langer CJ, McAleer CA, Bonjo CA, Litwin S, Millenson M, Kosierowski R, Blankstein K, Alexander R, Ozols RF. Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC). Eur J Cancer 2000; 36: 183–93
   PubMedGoogle Scholar
• Micha JP, Goldstein BH, Birk CL, Rettenmaier MA, Brown III JV. Abraxane in the treatment of ovarian cancer: The absence of hypersensitivity reactions. Gynecol Oncol 2006; 100(2): 437–8
   Google Scholar
• Ng R, Chen EX. Sorafenib (BAY 43-9006): Review of clinical development. Curr Clin Pharmacol 2006; 1: 223–8
   PubMedGoogle Scholar
• Ojima I. Guided molecular missiles for tumor-targeting chemotherapy-case studies using the second-generation taxoids as warheads. Acc Chem Res 2008; 41: 108–19
   PubMed Web of Science ®Google Scholar
• Panchagnula R. Pharmaceutical aspects of paclitaxel. Int J Pharm 1998; 172: 1–15
   Web of Science ®Google Scholar
• Pennacchietti S, Michieli P, Galluzzo M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3: 347–61
   PubMed Web of Science ®Google Scholar
• Rosen L. Antiangiogenic strategies and agents in clinical trials. Oncologist 2000; 1: 20–7
   Google Scholar
• Safavy A, Raisch KP, Khazaeli MB, Buchsbaum DJ, Bonner JA. Paclitaxel derivatives for targeted therapy of cancer: Toward the development of smart taxanes. J Med Chem 1999; 42: 4919–24
   PubMed Web of Science ®Google Scholar
• Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulation. Int J Pharm 2002; 235: 179–92
   PubMed Web of Science ®Google Scholar
• Steeg PS. Angiogenesis inhibitors: Motivators of metastasis?. Nat Med 2003; 9: 822–3
   PubMed Web of Science ®Google Scholar
• Thakkar H, Sharma RK, Mishra AK, Chuttani K, Murthy RR. Albumin microspheres as carriers for the antiarthritic drug celecoxib. AAPS Pharm Sci Tech 2005; 6: E65–73
   PubMed Web of Science ®Google Scholar
• Tyulina OV, Huentelman MJ, Prokopieva VD, Boldyrev AA, Johnson P. Dose ethanol metabolism affect erythrocyte hemolysis?. Biochim Biophys Acta (BBA) – Biomembranes 2000; 1535: 69–77
   PubMedGoogle Scholar
• Wang YB, Wang JC, Meng M, Zhang H, Zhang Q. Preparation and evaluation of docetaxel-loaded albumin nanoparticles for intravenous administration. J Chin Pharm Sci 2010; 19: 214–22
   Google Scholar
• Wilhelm SM, Carter C, Tang L. BAY 4329006 exhibits broad spectrum oral antitumor activity and targets the RAF /MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099–109
   PubMed Web of Science ®Google Scholar
• Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994; 330: 1253–9
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2008. Are the Number of Cancer Cases Increasing or Decreasing in the World? WHO [Online] Available at: http://www.who.int/features/qa/15/en/index.html. Accessed July 2010
   Google Scholar